Kenvue Inc. $KVUE Shares Acquired by Allstate Corp

Allstate Corp lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 98.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 140,900 shares of the company’s stock after buying an additional 69,944 shares during the period. Allstate Corp’s holdings in Kenvue were worth $2,431,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KVUE. Elyxium Wealth LLC acquired a new stake in Kenvue in the 4th quarter valued at $26,000. Physician Wealth Advisors Inc. increased its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Cornerstone Planning Group LLC increased its holdings in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after purchasing an additional 1,361 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after purchasing an additional 1,190 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on KVUE shares. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Finally, Canaccord Genuity Group raised their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.33.

Kenvue Stock Performance

Shares of KVUE stock opened at $17.66 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $23.90. The company’s 50-day simple moving average is $17.41 and its 200-day simple moving average is $17.46. The stock has a market capitalization of $33.92 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 1.34 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter last year, the company posted $0.24 earnings per share. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.59% of the stock is owned by corporate insiders.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.